As its next big bet, Sana inks long-term lease for manufacturing site for next-gen cell therapies

Josh Sullivan

A unicorn multiple times over, Sana Biotechnology hit Nasdaq running in February with its next-gen cell therapies still months away from the clinic. Now, Sana …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As its next big bet, Sana inks long-term lease for manufacturing site for next-gen cell therapies

Josh Sullivan

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

As its next big bet, Sana inks long-term lease for man­u­fac­tur­ing site for next-gen cell ther­a­pies

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

As its next big bet, Sana inks long-term lease for manufacturing site for next-gen cell therapies